- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 00:46 | FDA investigating Elevidys safety; Nektar shares spike on eczema data | ||
| Di | Lexeo to help launch spinout around RNA drugs for the heart | ||
| Di | Cassidy calls for delay to CDC vaccine meeting, challenging RFK Jr. | ||
| Di | New Amgen obesity drug data disappoint Wall Street | ||
| Di | Chasing rivals, Nuvalent to seek approval of targeted lung cancer drug | ||
| Mo | Relentless innovation: Bold exploration in advancing therapeutic options for every patient, every discovery | ||
| Mo | Top drug official at FDA reportedly set to exit next month | ||
| Mo | Cidara stock soars as antiviral drug succeeds in flu study | ||
| Mo | Illumina to buy SomaLogic in deal worth up to $425M | ||
| Mo | Novo abruptly ends obesity drug deal with Hims | ||
| Mo | Compass' big psychedelic study doesn't impress investors | ||
| Mo | [Podcast] Trial Trailblazers: Behind clinical breakthroughs | ||
| Mo | The rise of GLP-1 drugs: Transforming weight loss treatment | ||
| Fr | Prothena to lay off majority of staff; Zealand shares obesity drug data | ||
| Fr | A longer 'winter': Public funding slowdown heightens pressure on biotech startups | ||
| Fr | Gene therapy faces fresh uncertainty as two more top FDA officials depart | ||
| 18.06. | FDA approves twice-yearly shot of Gilead drug for HIV prevention | ||
| 18.06. | Scholar Rock drug preserves muscle in obesity trial | ||
| 18.06. | Draig, a brain drug startup, debuts with $140M to treat depression | ||
| 18.06. | FDA to speed reviews for drugs supporting 'national interests' | ||
| 18.06. | A startup banks $66M to pursue 'inclusive precision medicine' | ||
| 17.06. | Lilly to acquire Verve in $1B bet on gene editing for heart disease | ||
| 17.06. | FDA clears CSL's swelling disease drug; Regeneron loses 23andMe auction | ||
| 16.06. | Could the FDA take an indirect approach to regulate lab developed tests? | ||
| 16.06. | Roche, waving off study failures, commits to Phase 3 trials for Parkinson's drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .